AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10220188 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic foot compression combined with low-molecular-weight heparin for approximately 7 days after surgery
Number of subjects: 48
Study 10220188 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (control group)
Number of subjects: 48
Study 8570764 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diazepam (5 mg) pretreatment
Number of subjects: 10
Study 2353031 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg/day aspirin
Number of subjects: 0
Study 2353031 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg aspirin
Number of subjects: 0
Study 2353031 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/alternate day aspirin
Number of subjects: 0
Study 377471 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenbufen (600 mg per day for 4 weeks)
Number of subjects: 53
Study 377471 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (3.6 g per day for 4 weeks)
Number of subjects: 53
Study 31267502 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccine without booster
Number of subjects: 15459
Study 31267502 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccine with booster
Number of subjects: 15459
Study 28574133 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser (FSL)
Number of subjects: 10
Study 28574133 — intervention group
Group type: COMPARATOR
Intervention: Manual dissection
Number of subjects: 10
Study 25885011 — intervention group
Group type: EXPERIMENTAL
Intervention: augmented treatment (stimulant + parent training + risperidone)
Number of subjects: 168
Study 25885011 — intervention group
Group type: COMPARATOR
Intervention: basic treatment (stimulant + parent training + placebo)
Number of subjects: 168
Study 25885011 — intervention group
Group type: EXPERIMENTAL
Intervention: augmented treatment
Number of subjects: 168
Study 25885011 — intervention group
Group type: COMPARATOR
Intervention: basic treatment
Number of subjects: 168
Study 24111645 — intervention group
Group type: EXPERIMENTAL
Intervention: Icatibant (30 mg subcutaneously)
Number of subjects: 54
Study 21792113 — intervention group
Group type: EXPERIMENTAL
Intervention: Lordotic allografts
Number of subjects: 122
Study 21792113 — intervention group
Group type: COMPARATOR
Intervention: Parallel allografts
Number of subjects: 122
Study 21792113 — intervention group
Group type: EXPERIMENTAL
Intervention: Both graft types (lordotic and parallel)
Number of subjects: 122
Study 19422479 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA+VitE
Number of subjects: 0
Study 19422479 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA+placebo (P)
Number of subjects: 0
Study 19422479 — intervention group
Group type: COMPARATOR
Intervention: placebo (P)+placebo (P)
Number of subjects: 0
Study 17156694 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent diazepam prophylaxis (n = 68)
Number of subjects: 139
Study 17156694 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (n = 71)
Number of subjects: 139
Study 15570782 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile lithotripter treatment (2000 shock waves at 2.5 bars of air pressure, frequency of 8-10Hz, 3 treatments at 2-week intervals)
Number of subjects: 47
Study 15570782 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile lithotripter treatment
Number of subjects: 47
Study 15570782 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (clasp on elbow/heel to stop penetration of shock waves)
Number of subjects: 47
Study 11022179 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIFN-alpha
Number of subjects: 6
Study 11022179 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 6
Study 9374341 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene (1 mg or 1 microg/kg)
Number of subjects: 8
Study 9374341 — intervention group
Group type: COMPARATOR
Intervention: Naloxone (2 mg or 2 microg/kg)
Number of subjects: 8
Study 9374341 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene
Number of subjects: 8
Study 9374341 — intervention group
Group type: COMPARATOR
Intervention: Naloxone
Number of subjects: 8
Study 1586185 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus nasogastric feeding
Number of subjects: 43
Study 1586185 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nasogastric feeding
Number of subjects: 43
Study 1586185 — intervention group
Group type: COMPARATOR
Intervention: Transpyloric feeding
Number of subjects: 43
Study 2883828 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 0
Study 2883828 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 0
Study 2883828 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg
Number of subjects: 0
Study 2883828 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 15 mg
Number of subjects: 0
Study 2883828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28945649 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotissue Cliradex (CD)
Number of subjects: 26
Study 28945649 — intervention group
Group type: EXPERIMENTAL
Intervention: OCuSOFT Lid Scrubs Plus (OP)
Number of subjects: 26
Study 28945649 — intervention group
Group type: EXPERIMENTAL
Intervention: NovaBay Avenova (NA)
Number of subjects: 26
Study 28945649 — intervention group
Group type: EXPERIMENTAL
Intervention: TheraTears Theralid (TT)
Number of subjects: 26
Study 28945649 — intervention group
Group type: EXPERIMENTAL
Intervention: OCuSOFT OUST Demodex Swabstix (ODS)
Number of subjects: 26
Study 28945649 — intervention group
Group type: COMPARATOR
Intervention: Bausch+Lomb Sensitive Eyes Plus saline
Number of subjects: 26
Study 27323936 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic profile at 4 months of age
Number of subjects: 230
Study 27323936 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolite concentrations
Number of subjects: 230
Study 27323936 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at diagnosis using survival models
Number of subjects: 230
Study 24836273 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223 (50 kBq/kg, six intravenous injections, one every 4 weeks)
Number of subjects: 921
Study 24836273 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 921
Study 24836273 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223
Number of subjects: 921
Study 22800506 — intervention group
Group type: EXPERIMENTAL
Intervention: CaPRA (intervention)
Number of subjects: 50
Study 22800506 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 50
Study 20507387 — intervention group
Group type: COMPARATOR
Intervention: High-dose intravenous immunoglobulin (HD-IVIG) at a dosage of 400 mg/kg per day for 5 days as an adjuvant therapy with systemic steroid therapy and/or immunosuppressive agents.
Number of subjects: 0
Study 20507387 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin (HD-IVIG)
Number of subjects: 0
Study 18206732 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg/day)
Number of subjects: 124
Study 18206732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 15992641 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional navigator-gated magnetic resonance imaging (MR)
Number of subjects: 52
Study 15992641 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-slice multidetector row computed tomography (MDCT)
Number of subjects: 52
Study 14688811 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 69
Study 14688811 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 69
Study 11301670 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9164193 — intervention group
Group type: COMPARATOR
Intervention: Etoposide plus cisplatin (EP)
Number of subjects: 419
Study 9164193 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin, etoposide, and cisplatin (BEP)
Number of subjects: 419
Study 9164193 — intervention group
Group type: EXPERIMENTAL
Intervention: BEP
Number of subjects: 419
Study 8426316 — intervention group
Group type: COMPARATOR
Intervention: Monofocal implant (Group 1)
Number of subjects: 50
Study 8426316 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal implant (Group 2)
Number of subjects: 50
Study 3501902 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (DP) 75 mg and Acetylsalicylic acid (ASA) 325 mg thrice daily for 3 months
Number of subjects: 0
Study 3501902 — intervention group
Group type: COMPARATOR
Intervention: Placebo regimen identical to DP-ASA
Number of subjects: 0
Study 31882240 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibetan medicated bathing therapy in combination with conventional rehabilitation
Number of subjects: 444
Study 31882240 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 444
Study 29055624 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD)
Number of subjects: 210
Study 29055624 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 210
Study 29055624 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric assessment (GA)
Number of subjects: 210
Study 29055624 — intervention group
Group type: EXPERIMENTAL
Intervention: Karnofsky Performance Status (KPS)
Number of subjects: 210
Study 29055624 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative illness rating scale‐geriatrics (CIRS‐G)
Number of subjects: 210
Study 29055624 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasgow prognostic score (GPS)
Number of subjects: 210
Study 29055624 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic inflammatory and nutritional index (PINI)
Number of subjects: 210
Study 29055624 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental activities of daily living (IADL) from GA
Number of subjects: 210
Study 27865535 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic methylprednisolone (62.5 mg/mL)
Number of subjects: 60
Study 27865535 — intervention group
Group type: COMPARATOR
Intervention: Intratympanic gentamicin (40 mg/mL)
Number of subjects: 60
Study 25149995 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg daily)
Number of subjects: 42
Study 25149995 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 42
Study 23006808 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal auditory training (AT) for 8 weeks in APD and SLIa groups
Number of subjects: 30
Study 23006808 — intervention group
Group type: COMPARATOR
Intervention: c-ABR with background noise
Number of subjects: 30
Study 23006808 — intervention group
Group type: COMPARATOR
Intervention: c-ABR in silence
Number of subjects: 30
Study 23006808 — intervention group
Group type: COMPARATOR
Intervention: Behavioral assessment of auditory processing
Number of subjects: 30
Study 20863398 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplement (IS) - 20 mg iron
Number of subjects: 266
Study 20863398 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron + folic acid supplement (IFS) - 12.5 mg iron
Number of subjects: 266
Study 20863398 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplement (MMS) - 10 mg iron
Number of subjects: 266
Study 20863398 — intervention group
Group type: COMPARATOR
Intervention: Micronutrient-fortified complementary food (FCF) - 10 mg iron
Number of subjects: 266
Study 20863398 — intervention group
Group type: COMPARATOR
Intervention: Zinc + iron + ascorbic acid fortified water (FW) - 6.7 mg iron
Number of subjects: 266
Study 17766187 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational Video Group
Number of subjects: 0
Study 17766187 — intervention group
Group type: EXPERIMENTAL
Intervention: Documentation Group
Number of subjects: 0
Study 17766187 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 0
Study 16624398 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching units on giving advice to stop smoking (3 units, 1 day each)
Number of subjects: 956
Study 16624398 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 956
Study 12916465 — intervention group
Group type: EXPERIMENTAL
Intervention: STI-571 (Imatinib)
Number of subjects: 0
Study 12916465 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodality treatment
Number of subjects: 0
Study 12916465 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb-sparing procedures
Number of subjects: 0
Study 10812377 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat condition
Number of subjects: 30
Study 10812377 — intervention group
Group type: COMPARATOR
Intervention: Regular-fat condition
Number of subjects: 30
Study 8979323 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific, localized, exercise therapy
Number of subjects: 39
Study 8979323 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment only
Number of subjects: 39
Study 1424856 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous bronchodilator treatment (salbutamol in the first year and ipratropium bromide in the second year)
Number of subjects: 144
Study 1424856 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic bronchodilator treatment (salbutamol in the first year and ipratropium bromide in the second year)
Number of subjects: 144
Study 1424856 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous bronchodilator treatment
Number of subjects: 144
Study 1424856 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic bronchodilator treatment
Number of subjects: 144
Study 3874038 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac sulfoxide (200 mg b.i.d.)
Number of subjects: 15
Study 3874038 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac sulfide (100 mg b.i.d.)
Number of subjects: 15
Study 3874038 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (650 mg q.i.d.)
Number of subjects: 15
Study 3874038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31925845 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet Group (stored in distilled water)
Number of subjects: 40
Study 31925845 — intervention group
Group type: COMPARATOR
Intervention: Dry Group (stored in a dry container)
Number of subjects: 40
Study 29412167 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-centered 'tune-up' intervention (1-hour therapy sessions, 3 times/week for 2 weeks at 6 months postdischarge)
Number of subjects: 103
Study 29412167 — intervention group
Group type: COMPARATOR
Intervention: Control group (same exposure to assessment)
Number of subjects: 103
Study 29412167 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (tune-up and control)
Number of subjects: 103
Study 27375126 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal door-to-door delivery of HIV testing and referral to prevention and treatment services with immediate offer of anti-retroviral treatment regardless of clinical status
Number of subjects: 52500
Study 27375126 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal door-to-door delivery of HIV testing and referral to prevention and treatment services with offer of treatment in-line with national guidelines
Number of subjects: 52500
Study 27375126 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care control arm
Number of subjects: 52500
Study 24807330 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin and antibiotics
Number of subjects: 53
Study 24807330 — intervention group
Group type: COMPARATOR
Intervention: No perioperative prophylactic medications (Control)
Number of subjects: 53
Study 24807330 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Indomethacin and antibiotics vs Control)
Number of subjects: 53
Study 22143739 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 18
Study 22143739 — intervention group
Group type: COMPARATOR
Intervention: 4% articaine
Number of subjects: 18
Study 19740546 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 40
Study 19740546 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 40
Study 18279948 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (n=152)
Number of subjects: 298
Study 18279948 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=144)
Number of subjects: 298
Study 15860753 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 100 microg
Number of subjects: 7
Study 15860753 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 500 microg
Number of subjects: 7
Study 15860753 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg
Number of subjects: 7
Study 15860753 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with 100 microg FP and salmeterol
Number of subjects: 7
Study 15860753 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol in combination with FP
Number of subjects: 7
Study 12190841 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 1 mg daily plus intermittent NGM 90 micro g (3 days off, 3 days on)
Number of subjects: 322
Study 12190841 — intervention group
Group type: COMPARATOR
Intervention: E2 2 mg plus constant NETA 1 mg daily
Number of subjects: 322
Study 10530636 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride (50 to 150 mg/d)
Number of subjects: 189
Study 10530636 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine hydrochloride (50 to 150 mg/d)
Number of subjects: 189
Study 10530636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 8615540 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphoroorganic or carbaminate intoxications (Ia)
Number of subjects: 0
Study 8615540 — intervention group
Group type: COMPARATOR
Intervention: Ethylene glycol intoxication (Ib)
Number of subjects: 0
Study 8615540 — intervention group
Group type: EXPERIMENTAL
Intervention: Amanita phalloides poisoning (Id)
Number of subjects: 0
Study 8615540 — intervention group
Group type: COMPARATOR
Intervention: Chronic active hepatitis (II)
Number of subjects: 0
Study 8615540 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxogonine in vitro test
Number of subjects: 0
Study 2104090 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg cimetidine b.d.
Number of subjects: 0
Study 2104090 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg cimetidine nocte
Number of subjects: 0
Study 2104090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6988942 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimipramine 25 mg nocte
Number of subjects: 95
Study 6988942 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg nocte
Number of subjects: 95
Study 6988942 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg 3 times a day and 400 mg nocte (standard dose)
Number of subjects: 95
Study 30521044 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc combined with probiotics (Bifico)
Number of subjects: 50
Study 30521044 — intervention group
Group type: COMPARATOR
Intervention: Bifico (probiotics)
Number of subjects: 50
Study 28118062 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine supplementation (500 mg three times per day for two weeks)
Number of subjects: 16
Study 28118062 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine supplementation
Number of subjects: 16
Study 28118062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 26504842 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (diet and physical activity education and behavioural change techniques)
Number of subjects: 329
Study 26504842 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 329
Study 23392656 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity in ventromedial prefrontal cortex (vmPFC) during choice and feedback
Number of subjects: 0
Study 23392656 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity in dorsal anterior cingulate cortex (dACC) during choice and feedback
Number of subjects: 0
Study 23392656 — intervention group
Group type: EXPERIMENTAL
Intervention: vmPFC, mid-cingulate, and posterior cingulate cortex activity
Number of subjects: 0
Study 23392656 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback effects in vmPFC
Number of subjects: 0
Study 23392656 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback effects in dACC
Number of subjects: 0
Study 21234528 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokinesis‐block micronucleus (CBMN) assay
Number of subjects: 22
Study 21234528 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromosome aberration technique (CAT)
Number of subjects: 22
Study 21234528 — intervention group
Group type: COMPARATOR
Intervention: Comparison of CBMN assay and CAT
Number of subjects: 22
Study 19233765 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent antegrade blood cardioplegia with 300 mg of NAC
Number of subjects: 20
Study 19233765 — intervention group
Group type: COMPARATOR
Intervention: Intermittent antegrade blood cardioplegia without NAC (control group)
Number of subjects: 20
Study 19233765 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (with and without NAC)
Number of subjects: 20
Study 17578983 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection group (droperidol 2.5 mg)
Number of subjects: 160
Study 17578983 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous group (droperidol 1.25 mg/day)
Number of subjects: 160
Study 17578983 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined single (droperidol 1.25 mg) and continuous (droperidol 0.625 mg/day) group
Number of subjects: 160
Study 17578983 — intervention group
Group type: COMPARATOR
Intervention: Control group (no droperidol)
Number of subjects: 160
Study 15884202 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education and physical training (6 weeks education, 25 weeks training)
Number of subjects: 64
Study 15884202 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education and physical training
Number of subjects: 64
Study 15884202 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study 11831117 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic contrast medium Hypaque‐76 (n = 31)
Number of subjects: 62
Study 11831117 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonionic contrast medium Ultravist‐370 (n = 31)
Number of subjects: 62